Sobi announces a new research collaboration on the development of Gamifant in sepsis, which is to be presented at the ISICEM congress: Stockholm Thursday, March 20, 2025, 12:00 Hr ...

A study from St. Jude Children’s Research Hospital reveals that the protein VDAC2 acts as a “signal jammer” in tumors, ...

The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS ...

Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular ...

Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...

SAN DIEGO, Calif. (Ivanhoe Newswire) - A breakthrough in bladder cancer treatment is helping to save more lives. The American Cancer Society estimates that 83,000 new cases of bladder cancer will be ...

St. Jude researchers identified a protein, voltage-dependent anion channel 2 (VDAC2), that tumors use as a “signal jammer” to prevent cancer cell death and evade the immune system’s functioning.

Recent work in The EMBO Journal describes a new hybrid post-translational modification of proteins, composed of a poly-ubiquitin chain that is attached to a target protein via a mono-ADP-ribose (MAR) ...

A study from Emory University suggests that levodopa, a medication that increases dopamine levels in the brain, may help ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...